Evidence map›Paper›PMID 40041201›Full record

ArticleNeuro-oncology advances

ICAM-1 and IL-10 are associated with cognitive dysfunction using the MoCA test in glioma: Findings from the NCI Neuro-Oncology Branch Natural History Study.

Kaitlynn Slattery, McKenzie C Kauss, Dhaivat Raval, Emory Hsieh, Ann Choi, Tara S Davis, Kimberly R Robins, Hope Miller, Elizabeth Vera, Michelle L Wright and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kaitlynn SlatteryNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
McKenzie C KaussNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Dhaivat RavalNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Emory HsiehNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Ann ChoiNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Tara S DavisNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Kimberly R RobinsNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID https://orcid.org/0009-0007-7423-9873
Hope MillerNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Elizabeth VeraNational Cancer Institute (NCI) Office of Patient-Centered Outcomes Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Michelle L WrightNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Marta Penas-PradoNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Mark R GilbertNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-8935-1744
Tito MendozaNational Cancer Institute (NCI) Office of Patient-Centered Outcomes Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.
Terri S ArmstrongNational Cancer Institute (NCI) Office of Patient-Centered Outcomes Research, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-2414-0492
Vivian A GuedesNational Cancer Institute Neuro-Oncology Branch, National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-8478-2465

Funding

A Phase I Combination Study of Durvalumab and Vicinium in BCG refractory NMIBCZIABC011786 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI AGARWAL, PIYUSH · 2017 to 2019
$137k
Intramural NIH HHS ZIA BC011786
6 · The paper itself

Abstract

Background: Cognitive dysfunction is common among patients with malignant glioma, yet the underlying mechanisms of this dysfunction remain unclear. Protein markers of neurodegeneration, inflammation, and vascular damage have been associated with central nervous system pathology and with cognitive changes in neurological diseases, but their clinical utility in gliomas is unknown. This study examined the relationships between cognitive dysfunction, tumor isocitrate dehydrogenase (IDH) mutation status in gliomas, and a panel of blood-based protein biomarkers. Methods: This retrospective cohort study included 73 glioma patients with either IDH-mutant ( Results: Cognitive dysfunction was present in 53% of participants ( Conclusions: Cognitive dysfunction was associated with protein markers linked to vascular damage and inflammation regardless of tumor IDH status. Our findings suggest an association of cognitive dysfunction with heightened systemic inflammatory status that requires further interrogation for its role in pathophysiologic mechanisms.

Indexed as

biomarkerscognitive dysfunctioninflammationneurodegenerationtumor IDH mutation

Identifiers

PMID40041201
PMCPMC11879401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.